Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

FDA Approves Horizant To Treat Restless Legs Syndrome

April 7, 2011 By Bio-Medicine.Org

SILVER SPRING, Md., April 7, 2011 /PRNewswire-USNewswire/ — On
April 6, the U.S. Food and Drug Administration approved Horizant
Extended Release Tablets (gabapentin enacarbil), a once-daily
treatment for moderate-to-severe restless legs syndrome (RLS).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

RLS is a disorder that causes a strong urge to move the legs.
This urge often occurs with unpleasant feelings in the legs. People
who have RLS describe feeling pulling, itching, tingling, burning,
or aching in their legs, and moving the legs temporarily relieves
these feelings. The urge to move often happens when a person is
inactive, and the symptoms typically are worse in the evening and
early morning.

“People with restless legs syndrome can experience considerable
distress from their symptoms,” said Russell Katz, M.D., director of
the Division of Neurology Products in the FDA’s Center for Drug
Evaluation and Research. “Horizant provides significant help in
treating these symptoms.”  

The effectiveness of Horizant was studied in two 12-week
clinical trials in adults. The trials showed that people taking the
medication had an improvement in their RLS symptoms, compared with
people taking an inactive pill (placebo).

Horizant will be dispensed with an FDA-approved Medication Guide
that explains the drug’s uses and risks. Horizant may cause
drowsiness and dizziness and can impair a person’s ability to drive
or operate complex machinery.

Horizant contains gabapentin enacarbil that becomes gabapentin,
a drug used to treat seizures in people with epilepsy, when
absorbed into the body. All drugs used to treat epilepsy carry
warnings that they may cause suicidal thoughts and actions in a
small number of people. Horizant will have the same warning.

Horizant was developed by GlaxoSmithKline of Research Triangle
Park, N.C., and Xenoport of Santa Clara, Calif.

For information:

National Institute

‘/>”/>

SOURCE

Related Articles Read More >

How this device broke through the blood-brain barrier
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
An illustration showing the Artedrone Sasha thrombectomy catheter approaching a blood clot.
This microrobot system is designed to float inside a stroke patient for autonomous thrombectomy
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe